Key Takeaways
- Crop genomics funding has transitioned from large-scale platform rounds to targeted, niche-focused investments in specific biological outcomes.
- Recent seed and Series A rounds — such as Biographica’s £7M and Resurrect Bio’s $8.1M — reflect investors targeting disease resistance and AI-driven gene discovery.
- Pairwise’s Fulcrum® platform has shifted from proprietary asset to a widely licensed industry tool, signalling CRISPR’s transition to standardised infrastructure.
- The geographic scope of crop genomics investment has expanded significantly beyond the U.S. Corn Belt into Europe, Asia, and sub-Saharan Africa.
- The dominant news type in the sector has shifted from R&D announcements to commercial approvals, signalling industry-wide maturation.
The End of the Platform Era
Between 2014 and 2022, the defining investment logic in crop genomics was the platform play. Firms raised capital on the promise of foundational tools — AI-driven breeding systems, CRISPR genomic libraries, biological input platforms — and valuations reflected the breadth of what those tools might eventually address. The largest rounds were correspondingly large: Indigo Ag’s $100 million Series C in 2016, Inari’s $200 million Series D in 2021, and a succession of nine-figure raises for companies whose primary asset was their methodology.
That era has closed. The data from 2025 and 2026 shows a materially different pattern in crop genomics funding. The dominant investment structure is now smaller, more targeted, and oriented toward specific biological outcomes rather than generalised platforms.
Crop Genomics Funding in 2025–2026: What the Data Shows
The Precision Funding Pattern
Two recent entries illustrate the new investment logic. Biographica closed a £7 million seed round, with the capital directed specifically toward AI-driven gene discovery for disease resistance — a defined problem with a defined target market. Resurrect Bio raised $8.1 million in a Series A focused on a similarly bounded objective.
These are not anomalies. They reflect a consistent pattern in the current crop genomics funding environment: investors are placing smaller, more targeted bets on specific niches rather than backing general-purpose platforms and waiting for application discovery to follow.
“Funding is now surgical, targeting niche biological outcomes rather than general platforms.”
This shift in funding behaviour carries structural implications for how crop genomics companies are built. Firms raising under these conditions need to demonstrate a clear path from a specific edit to a specific commercial outcome. The era of raising on methodology alone has passed.
The Scale-Up Phase: What Came Before
To understand what has changed, it is useful to trace the prior phase. Between 2020 and 2024, the crop genomics sector saw a concentration of large-scale validation rounds — capital raised to prove that platforms developed in the early wave could be taken to market. Inari’s progression from a $200 million Series D through to a $144 million Series G in 2025 is an example of this trajectory. Pairwise moved through a $90 million Series B to a $40 million Series C specifically aimed at bringing gene-edited produce to commercial shelves.
In this phase, the primary risk being managed was commercial validation: could the tools actually be deployed at scale, and would buyers pay for the output? By 2025, enough of those questions had been answered to shift the funding conversation from platform validation to niche execution.
The CRISPR Standardisation Signal
From Proprietary Secret to Industry Tool
One of the more significant structural signals in the 2025–2026 crop genomics data is what has happened to CRISPR as an investment asset. Pairwise’s Fulcrum® platform — a proprietary CRISPR toolset that represented a meaningful competitive differentiator at the time of the firm’s earlier funding rounds — has been licensed to Wild Bioscience, Enza Zaden, and the International Rice Research Institute.
The decision to license broadly is a commercial strategy, but it also reflects a wider industry dynamic. CRISPR is no longer a proprietary technology frontier in crop genomics. It is becoming standardised infrastructure — a tool that enables differentiated outcomes rather than itself constituting the differentiator.
This parallels what happened to PCR in molecular biology, or sequencing in genomics more broadly. The technology becomes ubiquitous; the value migrates to what you do with it, and how quickly.
NBT Frameworks and the Regulatory Unlock
Accompanying the CRISPR standardisation is a regulatory shift that is materially changing the commercial calculus for crop genomics investment. New Breeding Technique frameworks, expanding across multiple jurisdictions in 2025 and 2026, allow precision-bred crops to be classified outside the traditional GMO regulatory pathway in an increasing number of markets.
The effect on investment timing is significant. Regulatory approval timelines have historically been a major source of uncertainty in crop genomics investment models. As NBT frameworks reduce the approval burden for precision-bred varieties — examples include FuturaGene’s activity in Brazil and Cibus in Ecuador — the path from funded research to commercial revenue compresses. This makes earlier-stage crop genomics investment more attractive on a risk-adjusted basis.
Geographic Expansion of Crop Genomics Funding
Beyond the Corn Belt
The geographic scope of crop genomics investment has broadened materially. For most of the period from 2014 to 2022, the majority of commercial activity tracked in the sector was concentrated in the U.S. Corn Belt — reflecting the dominance of corn and soybean traits in the investment mix.
The 2025–2026 data shows a different map. European activity has increased, with Belgian institute VIB and Dutch firm Rijk Zwaan both active in heat-stable and aphid-resistant variety development targeting compliance with Green Deal agricultural standards. In the Global South, the Gates Foundation and CGIAR — operating through IRRI — are appearing with regularity in partnership announcements, including the BioCap project in Rwanda.
This geographic diversification is not merely a story about market expansion. It reflects the changed trait agenda: climate resilience and food security traits are most commercially relevant in geographies facing the highest climatic pressure, and that pressure is disproportionately concentrated outside the traditional centres of crop genomics investment.
Read the complete report here.
